Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma

Modern Pathology

Volumn 26, Issue 10, 2013, Pages 1338-1345

  Zhou, Yi ^a,b   Fan, Xiangshan ^a   Routbort, Mark ^a   Cameron Yin, C ^a   Singh, Rajesh ^a   Bueso Ramos, Carlos ^a   Thomas, Deborah A ^a   Milton, Denái R ^a   Medeiros, L Jeffrey ^a   Lin, Pei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Early T precursor; Immunophenotype; Prognosis; T acute lymphoblastic leukemia lymphoma; TdT

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; CHROMOSOME ABERRATION; CONTROLLED STUDY; DIPLOIDY; EARLY T PRECURSOR; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRANULOCYTIC SARCOMA; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LEUKOCYTE COUNT; LYMPHOBLAST; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRE T LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; T ACUTE LYMPHOBLASTIC LEUKEMIA; T LYMPHOBLAST; T LYMPHOBLASTIC LYMPHOMA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DNA NUCLEOTIDYLEXOTRANSFERASE; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE;

EID: 84885019279     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.78     Document Type: Article

References (35)

1. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29: 551-565.
2. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosomenegative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27: 911-918.
3. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101: 2788-2801.
4. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009;114: 5136-5145.
5. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104: 1624-1630.
6. Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 2009;27: 3363-3369.
7. Seegmiller AC, Kroft SH, Karandikar NJ, et al. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol 2009;132: 940-949.
8. Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003;127: 42-48.
9. Saab GA, Carloss H. Lymphoblastic lymphoma without TdT. N Engl J Med 1980;302: 969-970.
10. Shurin SB, Scillian JJ. Absence of terminal transferase may predict failure of remission induction in childhood ALL. Blood 1983;62: 81-84.
11. Faber J, Kantarjian H, Roberts MW, et al. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med 2000;124: 92-97.
12. Brcic I, Labar B, Peric-Balja M, et al. Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient. Int J Hematol 2008;88: 189-191.
13. Roshal M, Fromm JR, Winter S, et al. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry B Clin Cytom 2010;78: 139-146.
14. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107: 1116-1123.
15. Raff T, Gokbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109: 910-915.
16. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111: 5477-5485.
17. Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115: 4657-4663.
18. Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol 2012;156: 358-365.
19. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10: 147-156.
20. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9: 1783-1786.
21. Drexler HG, Menon M, Minowada J. Incidence of TdT positivity in cases of leukemia and lymphoma. Acta Haematol 1986;75: 12-17.
22. Patel JL, Smith LM, Anderson J, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol 2012;159: 454-461.
23. Thiel E, Kranz BR, Raghavachar A, et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989;73: 1247-1258.
24. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999;93: 3931-3939.
25. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106: 3760-3767.
26. Baak U, Gokbuget N, Orawa H, et al. Thymic adult T-cell acute lymphoblastic leukemia stratified in standard- and high-risk group by aberrant HOX11L2 expression: experience of the German multicenter ALL study group. Leukemia 2008;22: 1154-1160.
27. Baldus CD, Burmeister T, Martus P, et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006;24: 4714-4720.
28. Chiusa L, Francia di Celle P, Campisi P, et al. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica 2006;91: 270-271.
29. Heesch S, Goekbuget N, Stroux A, et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010;95: 942-949.
30. Maroulakou IG, Bowe DB. Expression and function of Ets transcription factors in mammalian development: a regulatory network. Oncogene 2000;19: 6432-6442.
31. Anderson MK, Hernandez-Hoyos G, Diamond RA, et al. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999;126: 3131-3148.
32. Tanner SM, Austin JL, Leone G, et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA 2001;98: 13901-13906.
33. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481: 157-163.
34. Hoehn D, Medeiros LJ, Chen SS, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 2012;137: 213-219.
35. Bogue M, Gilfillan S, Benoist C, et al. Regulation of N-region diversity in antigen receptors through thymocyte differentiation and thymus ontogeny. Proc Natl Acad Sci USA 1992;89: 11011-11015.